fbpx

Pipeline

PRODUCT CANDIDATES

PLUS THERAPEUTICS is focused on developing innovative chemotherapeutics and radiotherapeutics for rare cancers that address unmet medical and market needs. Occasionally, despite the administration of the best available patient care, cancer comes back. When this happens, it is called a recurrence or relapse.

Today PLUS THERAPEUTICS’ lead product candidates are intended to treat recurrent glioblastoma and relapsed small cell lung cancer. These are rare, incurable, and often fatal diseases for which there have been very few new treatments approved – only 3 since 2005 for recurrent glioblastoma and only 1 since 1998 for relapsed small cell lung cancer. PLUS THERAPEUTICS is looking to offer new treatment options to these patients and their healthcare providers.

Patented RNL™

BMEDA-Chelated Rhenium NanoLiposome

Recurrent Glioblastoma

Patented DocePLUS™

Albumin-Stabilized PEGylated Liposomal Docetaxel

Relapsed Small Cell Lung Cancer

DEVELOPMENT STATUS

Our pipeline is founded upon promising data generated in a variety of preclinical studies and company-sponsored clinical trials.

Radiotherapeutics
Indication
Delivery
Designation(s)
Funding
Development Status
RNL™
BMEDA-Chelated Rhenium NanoLiposome
Recurrent GlioblastomaIntratumoral+ FDA Orphan Drug
+ FDA Fast Track
NIH/NCIEnrolling U.S. Phase 1/2 Clinical Trial
RNL™
BMEDA-Chelated Rhenium NanoLiposome
Leptomeningeal CarcinomatosisIntrathecal or Intracerebroventricular
-
-
Late-Stage Preclinical
RNL™
BMEDA-Chelated Rhenium NanoLiposome
Peritoneal CarcinomatosisIntraperitoneal
-
-
Late-Stage Preclinical
RNL™
BMEDA-Chelated Rhenium NanoLiposome
Head & Neck Squamous Cell CarcinomaIntratumoral
-
-
Late-Stage Preclinical

PLUS THERAPEUTICS has an open FDA-approved IND and an active, enrolling, U.S. multi-center Phase 1/2 clinical trial of patented RNL™ for recurrent glioblastoma. To learn more about patented RNL™, click here.  To learn more about the ReSPECT™ Clinical Trial, click here.

Chemotherapeutics
Indication(s)
Delivery
Designation
Funding
Development Status
Patented DocePLUS™
Albumin-Stablized PEGylated Liposomal Docetaxel
+ Solid Tumor
+ Small Cell Lung Cancer
IntravenousFDA Orphan Drug
-
Published U.S. Phase 1 Clinical Trial
Generic DoxoPLUS™
PEGylated Liposomal Doxorubicin
+ Breast Cancer
+ Ovarian Cancer
+ Multiple Myeloma
+ Kaposi's Sarcoma
Intravenous
-
-
Completed Clinical Bioequivalence Versus CAELYX®

PLUS THERAPEUTICS has an open FDA-approved IND for patented DocePLUS™. We have completed and published results from a 29 patient U.S. Phase 1 clinical trial in solid tumors. We are preparing to initiate a Phase 2 clinical trial with patented DocePLUS™ as a second-line therapy for relapsed small cell lung cancer. To learn more about patented DocePLUS™, click here.

PLUS THERAPEUTICS is seeking divestiture opportunities for its complex generic DoxoPLUS™ asset. PLUS THERAPEUTICS has completed a substantial amount of nonclinical and clinical development, including a bioequivalence clinical study of DoxoPLUS™ versus CAELYX®. Much of the data generated can be used to support regulatory filings and approvals in Europe, China, the United States, and other countries/regions. To learn more about complex generic DoxoPLUS™, click here.